A blood test taken years before cancer appears may hold a warning sign for men’s long-term health. A large international study found that men with very low testosterone were more likely to be diagnosed with cancer and more likely to die from it later in life. The link was broad, but it came with an [...]A negative scan does not always mean recurrent prostate cancer is nowhere to be found. Sometimes, the disease may simply be too small or too faint to appear yet. New research suggests that repeating a PSMA PET scan later can reveal cancer that was missed the first time. Among patients with rising prostate-specific antigen (PSA) [...]For many men diagnosed with advanced prostate cancer, one of the biggest concerns is how long treatment will continue working. Although hormone therapy can slow the disease for years, prostate cancer often finds ways to adapt and eventually becomes resistant. Once this happens, treatment becomes more complicated and the risk of disease progression increases. Researchers […]
The post New Treatment Greatly Benefit Men with Aggressive Prostate Cancer appeared first on Knowridge Science Report.
A groundbreaking hospital-based study conducted in India sheds new light on the complex and often controversial relationship between lifestyle factors and prostate cancer risk. Published in the April 28, 2026 issue of Oncoscience, this investigation provides intriguing evidence that certain modifiable habits, specifically coffee and meat consumption, may significantly reduce the likelihood of developing prostate cancer among men. This revelation emerges despite prostate cancer being the world’s second most prevalent malignancy in men and a critical contributor to cancer-related mortality.
The research was spearheaded by Maya Kulshekar and Anuradha B. Patil at the Department of Biochemistry, Jawaharlal Nehru Medical College, part of the KLE Academy of Higher Education and Research in Karnataka, India. Their work comes at a crucial moment when the incidence of prostate cancer in India is poised to rise markedly, underscoring the urgent need to identify interventions grounded in modifiable risk behaviors.
In this rigorously designed study, 72 men with histopathologically confirmed prostate cancer were compared to 132 control individuals diagnosed with benign prostatic hyperplasia (BPH). The investigators carefully examined a suite of lifestyle factors—ranging from tobacco use and alcohol consumption to dietary patterns including tea, coffee, and meat intake, as well as occupational exposure linked to farming. Thorough multivariate logistic regression analyses allowed the team to adjust for confounding variables, thereby refining the associations between these factors and prostate cancer risk.
The findings revealed a striking inverse association between coffee consumption and prostate cancer risk, translating to an approximate 65% reduction in odds after adjustment for potential confounders. Meat consumption similarly demonstrated a protective effect, associated with a roughly 48% decreased risk. These results challenge some conventional nutritional beliefs and highlight the nuanced role diet may play in modulating prostate oncogenesis.
Contrastingly, the study found no statistically significant correlation between alcohol consumption, tobacco chewing, smoking, tea intake, or farming-related occupational exposure and prostate cancer once confounding factors were accounted for. Initial univariate analyses suggested elevated risk linked to smoking and tobacco chewing; however, these associations dissipated under multivariable scrutiny, suggesting the potential influence of other interacting factors.
The biochemical mechanisms underpinning these associations were thoughtfully explored by the authors. Coffee is a complex beverage rich in bioactive compounds including caffeine, cafestol, kahweol, and a spectrum of antioxidant polyphenols. These molecules have been extensively studied for their anti-inflammatory and antioxidant properties, implicating them in pathways that may suppress malignant transformation or tumor progression. Their capacity to modulate cellular stress responses, DNA repair, and immune regulation positions coffee as a potent functional food in cancer prevention paradigms.
Similarly, meat contains constituents such as trans-vaccenic acid, an unsaturated fatty acid that has been observed in some experimental models to influence immune responses and cellular signaling pathways relevant to oncogenesis. Notwithstanding, the study authors caution that the protective role of meat is complicated by the heterogeneity inherent in types of meat, cooking methods, and quantity consumed—parameters that were not stratified in this investigation. The metabolic and molecular consequences of processed versus unprocessed meats or the generation of carcinogenic compounds during certain cooking processes remain pivotal confounders warranting further rigorous examination.
This research importantly acknowledges the broader scientific context where prior epidemiological studies have reported inconsistent and at times contradictory findings regarding coffee, meat, tobacco, tea, and alcohol in relation to prostate cancer risk. This inconsistency may stem from differences in study design, dietary assessment methods, population genetics, and environmental factors across cohorts. The current study’s contribution lies in focusing on an Indian population, thereby addressing a geographic and ethnic gap in the literature.
The methodological design, while robust, is not without limitations. The single-center hospital-based sample, and relatively modest cohort size, may affect the generalizability of the findings. Additionally, potential recall bias in self-reported lifestyle habits and the absence of quantitative dietary intake measures restrict the granularity of exposure assessment. The authors advocate for larger, multicenter, and longitudinal studies with comprehensive dietary and lifestyle quantification to validate and expand upon these preliminary observations.
This investigation marks an important step toward understanding how modifiable lifestyle factors could temper the risk of prostate cancer. By highlighting coffee and meat intake as potentially protective, the study invites a reevaluation of dietary guidelines and preventive oncology strategies within the Indian context and beyond. The mechanistic insights further fuel the search for bioactive compounds that could be leveraged in therapeutic or nutraceutical formulations.
Ultimately, these findings reinforce the imperative for personalized medicine approaches that integrate lifestyle, genetic, and environmental data to optimize cancer prevention and management. They also echo broader calls within the oncological community to pursue open-access, multidisciplinary research that bridges molecular science with public health imperatives.
While the findings demand cautious interpretation, they open an exciting avenue for leveraging everyday dietary choices as part of a comprehensive prostate cancer risk reduction strategy. As prostate cancer incidence is projected to escalate, especially in rapidly modernizing societies, these insights provide a timely beacon for clinicians, researchers, and policy makers alike.
The study’s implications extend beyond prostate cancer, emphasizing a holistic perspective on how complex interplays of diet, lifestyle, and biological mechanisms coalesce to impact carcinogenesis. It epitomizes the potential for traditional epidemiological research, augmented by advanced statistical modeling, to generate actionable knowledge that may ultimately improve patient outcomes on a population scale.
Researchers and clinicians interested in this expanding field are encouraged to follow ongoing and future work from this team and related cohorts worldwide, as the quest to decipher modifiable risk factors of prostate cancer continues to gain precision and impact.
Subject of Research: People
Article Title: Modifiable risk factors of prostate cancer: Insights from a hospital-based study
News Publication Date: 28-Apr-2026
Web References: https://doi.org/10.18632/oncoscience.657
Image Credits: Copyright © 2026 Kulshekar et al. Creative Commons Attribution License (CC BY 4.0)
Keywords: modifiable risk factors, prostate cancer, awareness, India, molecular mechanism
In the ongoing battle against prostate cancer, one of the most formidable obstacles researchers and clinicians face is the cancer cells’ remarkable ability to develop resistance to treatments. These malignant cells employ sophisticated adaptive mechanisms to survive the onslaught of therapeutic agents, rendering many promising drugs less effective over time. A groundbreaking study led by Dr. Noel Warfel and his team at the MUSC Hollings Cancer Center has uncovered a hitherto unrecognized pathway that explains why certain protein-targeting drugs falter, offering fresh hope for more potent and durable therapies. Published in the latest issue of Cancer Letters, this research not only elucidates a novel survival mechanism in prostate cancer cells but also proposes an innovative therapeutic strategy to circumvent drug resistance.
At the heart of this discovery lies PIM1, a serine/threonine kinase well-known for its role in promoting prostate tumor growth, survival, and resistance to conventional therapies. Despite the development of various PIM1 inhibitors aimed at curbing its kinase activity, clinical success has been elusive, particularly in patients with solid tumors. The study probes the inadequacies of these conventional inhibitors and shifts the focus towards understanding the multifaceted biology of PIM1. Dr. Warfel’s work reveals that simply inhibiting PIM1’s enzymatic function does not fully neutralize its cancer-supporting properties, as the protein wields influence beyond its traditional kinase signaling.
Classically, kinase inhibitors designed to target PIM1 have been intended to block its enzymatic activity—effectively halting the phosphorylation events that drive tumor progression. However, Warfel’s team discovered that these drugs paradoxically cause an accumulation of PIM1 protein within cancer cells. Rather than being degraded, the surplus protein lingers and continues to facilitate cancer cell survival through kinase-independent mechanisms. This phenomenon results in a paradoxical biological double-edged sword: while inhibiting the enzyme’s catalytic function, the drugs inadvertently empower cancer cells with a fresh lifeline to resist death.
Key to this newly uncovered survival mechanism is the interaction between PIM1 and another protein known as HMGB1, a chromatin-binding factor usually confined to the nucleus. HMGB1 has a pivotal role in orchestrating cellular responses to DNA damage, but when PIM1 protein is abundant, these two form a complex that relocates HMGB1 from the nucleus to the cytoplasm. Once in the cytoplasm, HMGB1 ignites autophagy—a cellular recycling process that allows cancer cells to eliminate dysfunctional organelles, particularly damaged mitochondria.
Damaged mitochondria are notorious sources of reactive oxygen species and oxidative stress, conditions that can precipitate cell death. By facilitating the clearance of these harmful mitochondria, the PIM1-HMGB1 axis effectively lowers oxidative stress, bestowing cancer cells with a remarkable resilience against therapies designed to induce lethal damage. This mitophagy-driven defense mechanism enables prostate cancer cells to survive treatment regimens that would otherwise be effective, thus revealing a sophisticated layer of therapeutic evasion.
The implications of these findings are profound. They underscore a fundamental flaw in the current approach to drug design for kinase targets: the assumption that merely inhibiting the catalytic activity of a protein suffices to halt its oncogenic functions. Dr. Warfel emphasizes that the presence of the PIM1 protein itself—irrespective of its enzymatic activity—can sustain drug resistance, signaling a need for therapies that eliminate the protein entirely rather than merely neutralizing its kinase function.
In response to this challenge, the research team previously engineered a novel class of molecules known as proteolysis-targeting chimeras (PROTACs), specifically designed to induce the degradation of the PIM1 protein. Their lead compound, PIMTAC, capitalizes on the cell’s own proteasomal machinery to selectively tag and destroy PIM proteins, rather than simply inhibiting their kinase activity. Laboratory experiments and mouse model studies demonstrate that PIMTAC significantly enhances cancer cell death by increasing oxidative stress and disrupting the HMGB1-mediated survival pathway, outperforming conventional PIM1 inhibitors.
PIMTAC’s capacity to degrade PIM1 addresses both the signaling-dependent and -independent functions of the protein, offering a more comprehensive treatment strategy. By eliminating the kinase-independent survival effects, this approach holds promise for overcoming the persistent issue of drug resistance that hampers the efficacy of current therapies. The data suggest that this novel method could extend beyond prostate cancer to other malignancies where PIM proteins contribute to disease progression, including breast, lung, and various hematologic cancers.
While the development of PIMTAC represents a significant advance, the research remains in its preclinical phase. Challenges such as optimizing systemic delivery of the relatively large PROTAC molecule and improving its tumor-targeting specificity need to be addressed before clinical trials can commence. However, the insights gleaned from these studies reaffirm the importance of in-depth biological exploration of cancer targets, even those that have been the focus of research for many years.
This work also reflects a broader paradigm shift in oncology drug development. Increasing recognition of non-catalytic roles played by kinases and other oncogenic proteins suggests a future where protein degradation technologies might supersede traditional enzyme inhibition. Dr. Warfel envisions a landscape in which cancer therapeutics not only disable protein functions but remove the underlying protein itself, thereby dismantling multiple cancer-supportive mechanisms simultaneously.
Ultimately, this study epitomizes the continuous innovation and relentless inquiry needed to outsmart cancer’s adaptability. By uncovering a concealed survival pathway and offering a way to dismantle it, researchers add a crucial weapon to the anticancer arsenal. For patients battling advanced prostate cancer, particularly those facing the frustrations of treatment resistance, such advances kindle hope for more effective, durable therapies that can translate to improved outcomes and prolonged survival.
The journey from laboratory breakthrough to clinical application involves numerous hurdles, but endeavors like Dr. Warfel’s offer a compelling blueprint for future cancer research. Exploring the nuanced biology of proteins like PIM1 not only deepens scientific understanding but also fuels the creation of revolutionary treatments with the potential to save lives. This study stands as a testament to the power of reexamining established targets with fresh eyes and cutting-edge techniques, underscoring the importance of basic and translational research in reshaping cancer therapy.
As the medical community continues to explore the complexities of tumor biology, the integration of protein-targeting strategies such as PROTACs will likely play an instrumental role in overcoming therapeutic resistance. The PIM1-HMGB1 interaction and its influence on mitophagy highlight how intricate and multifaceted cancer cell survival mechanisms can be. Future investigations will undoubtedly build upon this foundational work, expanding the horizon of possibilities for precise, effective, and personalized cancer treatment modalities.
Subject of Research: Cells
Article Title: Kinase-independent signaling by PIM1 promotes drug resistance by increasing mitophagy and reducing oxidative stress
News Publication Date: 27-May-2026
Web References:
References: DOI: 10.1016/j.canlet.2026.218611
Image Credits: Medical University of South Carolina, Photo by Clif Rhodes
Keywords: Kinase inhibitors, Prostate cancer, Autophagy
In the ongoing battle against prostate cancer, researchers have uncovered a biochemical pathway that promises to revolutionize treatment strategies. A recent study by Zhang, H., Feng, T., Lv, M., and colleagues, published in Cell Death Discovery, reveals how quinolinic acid, a metabolite derived from the enzyme HAAO, significantly influences androgen receptor (AR) signaling via an FDPS-dependent mechanism. This discovery not only deepens our understanding of prostate cancer biology but also highlights a novel avenue for enhancing the efficacy of combination therapies.
Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, with androgen receptor signaling playing a pivotal role in disease progression and therapy resistance. Androgen deprivation therapies (ADT) have long been the frontline treatment; however, many patients eventually develop castration-resistant prostate cancer (CRPC), underscoring the urgent need for new molecular targets and therapeutic strategies. The study conducted by Zhang and colleagues brings to light the critical interplay between metabolites in the kynurenine pathway and AR signaling, potentially offering new hope for overcoming therapeutic resistance.
Central to their findings is quinolinic acid (QA), a metabolite produced downstream of 3-hydroxyanthranilic acid oxygenase (HAAO) activity within the kynurenine pathway of tryptophan metabolism. Quinolinic acid has traditionally been studied for its neurotoxic properties, but this research innovatively identifies QA as a key modulator within prostate cancer cells. The team demonstrated that HAAO expression is markedly elevated in prostate cancer tissues, correlating with advanced disease stages and poorer prognosis.
Mechanistically, quinolinic acid appears to fuel FDPS (farnesyl diphosphate synthase)-dependent androgen receptor signaling. FDPS is a crucial enzyme in the mevalonate pathway, responsible for the synthesis of isoprenoids, which are vital for protein prenylation and cellular proliferation. The researchers showed that elevated QA enhances FDPS activity, leading to increased AR signaling activity. This hyperactivation of AR signaling amplifies cancer cell growth and survival, facilitating resistance to standard therapies.
What makes this discovery particularly compelling is the demonstration that modulating levels of quinolinic acid can sensitize prostate cancer cells to combination therapeutic approaches. The study revealed that inhibiting HAAO or reducing quinolinic acid production diminishes FDPS-dependent AR signaling, thereby suppressing tumor cell proliferation and improving the effectiveness of anti-androgen drugs. These findings suggest a promising therapeutic window where targeting metabolic pathways can synergize with hormonal therapies to overcome resistance.
The implications of these results extend beyond a simple metabolic snapshot. They connect two major biological systems—the kynurenine pathway and the mevalonate pathway—each with independent significance in cancer biology but now linked through quinolinic acid’s regulatory effects. This metabolic crosstalk introduces a paradigm shift in how metabolic intermediates can be exploited to influence oncogenic signaling cascades.
Moreover, the study utilized a combination of advanced molecular techniques including transcriptomics, metabolomics, and functional assays in both in vitro and in vivo models. These comprehensive approaches validated the critical role of HAAO-derived quinolinic acid and its impact on FDPS expression and activity. Importantly, patient-derived xenografts and clinical data underscored the translational relevance of the findings, suggesting readiness for clinical exploration.
Therapeutically, the prospect of combining HAAO inhibitors or agents targeting quinolinic acid synthesis with established anti-androgen therapies such as enzalutamide marks a significant advancement. This combination strategy could potentially prevent or delay the onset of treatment resistance, a major hurdle in managing advanced prostate cancer. Additionally, the study hints at the broader possibility of targeting metabolic vulnerabilities in other androgen-driven cancers.
From a mechanistic perspective, the identification of quinolinic acid as an oncometabolite challenges previous notions relegating it to neurotoxicity roles. It invites further exploration of how metabolic byproducts can act as signaling molecules within the tumor microenvironment, influencing cancer cell behavior and treatment outcomes. This insight opens doors for novel biomarkers that can predict response to therapy and guide personalized medicine approaches.
Furthermore, the study paves the way to investigate whether similar metabolic dependencies exist in other malignancies where steroid hormone receptor signaling is critical. If so, the HAAO-FDPS-AR axis may become a universal target across multiple cancer types, broadening the scope of therapeutic interventions beyond prostate cancer alone.
On the molecular signaling axis, the team discovered that quinolinic acid’s impact on FDPS promotes AR nuclear translocation and transcriptional activity, leading to enhanced expression of AR target genes that drive proliferation and survival pathways. This detailed mechanistic insight provides concrete targets for pharmacological intervention and biomarker development.
This groundbreaking study also raises important questions about the metabolic plasticity of cancer cells and their ability to adapt biosynthetic pathways to sustain oncogenic signaling. Understanding how cancer cells leverage metabolites like quinolinic acid could illuminate resistance mechanisms and identify vulnerabilities exploitable by combination therapies.
In conclusion, the elucidation of HAAO-derived quinolinic acid as a central actor fueling FDPS-dependent androgen receptor signaling heralds a novel metabolic axis driving prostate cancer progression and therapy resistance. By bridging metabolic biochemistry and signal transduction, the research sets the stage for innovative treatment paradigms that combine metabolic inhibition with hormonal therapy, potentially transforming patient outcomes in prostate cancer and beyond.
Zhang and colleagues’ work exemplifies the power of integrative omics and translational research in unraveling complex cancer biology, inviting the scientific community to rethink how metabolic intermediates can be harnessed in the fight against malignancy. As research advances, the HAAO-quinolinic acid-FDPS-AR signaling axis may well become a cornerstone in precision oncology strategies targeting prostate cancer metabolism and hormone receptor signaling.
Subject of Research: Prostate cancer metabolism and androgen receptor signaling modulation by HAAO-derived quinolinic acid.
Article Title: HAAO-derived quinolinic acid fuels FDPS-dependent AR signaling and sensitizes prostate cancer to combination therapy.
Article References:
Zhang, H., Feng, T., Lv, M. et al. HAAO‑derived quinolinic acid fuels FDPS‑dependent AR signaling and sensitizes prostate cancer to combination therapy. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03203-x
Image Credits: AI Generated
Login